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PENILAIAN IMPAK PROGRAM PEMANTAUAN UBAT-UBATAN DI 
RUMAH PESAKIT TERHADAP PEMATUHAN UBAT DI KALANGAN 
PESAKIT YANG DIDIAGNOS DENGAN SKIZOFRENIA DI DAERAH 
KINTA, MALAYSIA 
 
ABSTRAK 
 
Program pemantauan ubat-ubatan di rumah adalah untuk memberikan 
kesinambungan penjagaan pesakit dari institusi penjagaan kesihatan ke rumah 
pesakit. Namun demikian, impak sebenar program HMR di Malaysia adalah kurang 
diketahui. Kajian ini adalah untuk menilai impak program HMR terhadap pesakit 
skizofrenia dari segi pematuhan dan pengetahuan ubat, kualiti hidup, kepuasan 
kepada program dan jumlah penjimatan kos daripada stok lampau ubat-ubatan. 
Kajian prospektif longitudinal ini dijalankan dari September 2012 hingga Disember 
2013 dan melibatkan satu pensampelan mudah sejumlah 133 pesakit skizofrenia di 
bawah jagaan „Home Care Team‟ Hospital Bahagia Ulu Kinta. Selepas mendapat 
persetujuan bertulis, pesakit-pesakit telah dilawati oleh pegawai farmasi untuk 
menjalankan kajian komprehensif penggunaan ubat dan memberikan kaunseling 
ubat secara individu di rumah. Borang pengumpulan data yang standard telah 
digunakan untuk mengumpul data dari pesakit semasa lawatan pertama (garis asas), 
lawatan kedua (selepas sebulan), lawatan ketiga (selepas tiga bulan) dan lawatan 
keempat (selepas enam bulan). Pematuhan ubat telah dinilai dengan skala 
„Medication Adherence Rating Scale‟ (MARS) yang telah disahkan dan juga kaedah 
kiraan pil. Pengetahuan pesakit pada ubat antipsikotik dan kepuasan terhadap 
program HMR telah dinilai dengan borang soal selidik yang standard digubal oleh 
xi 
 
penyelidik bagi projek ini. Kualiti hidup pesakit telah dinilai dengan skala “Sheehan 
Disability Scale” (SDS). Sebarang penyimpanan ubat-ubatan yang berlebihan telah 
dikumpul dan direkod untuk analisis penjimatan kos. Purata umur untuk 133 
pesakit-pesakit adalah 41.76 (SD 8.86) tahun dan nisbah lelaki kepada perempuan 
adalah lebih kurang sama (54.9% vs 45.1%). Skor MARS menunjukkan pematuhan 
ubat telah bertambah baik dengan nyata pada setiap lawatan [lawatan pertama: 
median MARS = 9 (IQR 3) vs lawatan keempat: median MARS = 10 (IQR 1), p 
<0.001] manakala kaedah kiraan pil juga menunjukkan bahawa peratusan dos yang 
diambil mempunyai pencapaian yang sangat ketara selepas lawatan keempat 
[lawatan pertama: median = 67.1% (IQR 92.1%) vs lawatan keempat: median = 
97.5% (IQR 14.3%), p <0.001]. Skor pengetahuan juga telah bertambah baik dengan 
nyata selepas implementasi program HMR [lawatan pertama: 5 (IQR 2.5) vs lawatan 
keempat: 8 (IQR 1.0), p <0.001]. Dari segi kualiti hidup pesakit, terdapat 
peningkatan yang nyata bagi komponen „sosial‟ dan „keluarga‟ selepas enam bulan 
susulan (p  0.001). Namun demikian, tiada perbezaan yang nyata didapati pada 
keseluruhan kualiti hidup pesakit (p = 0.600) dan pada komponen „kerja‟ (p = 0.486). 
Pengurangan pembaziran ubat adalah sebanyak 26.5% selepas enam bulan program 
HMR. Pada akhir kajian, pesakit-pesakit  menunjukkan kepuasan positif dan 
penerimaan terhadap program HMR yang diberikan oleh pegawai farmasi. Secara 
kesimpulan, program HMR mempunyai impak positif pada pesakit dari segi 
pematuhan ubat, pengetahuan ubat antipsikotik, pengurangan pembaziran ubat, 
kepuasan perkhidmatan dan kualiti hidup pada komponen 'sosial' dan 'keluarga'. 
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EVALUATION OF THE IMPACT OF HOME MEDICATION REVIEW 
PROGRAM ON ADHERENCE AMONG PATIENTS DIAGNOSED WITH 
SCHIZOPHRENIA AT KINTA DISTRICT, MALAYSIA 
 
ABSTRACT  
 
Home medication review (HMR) program is to provide continuity of patient‟s care 
from healthcare institutions to patients‟ home. However, little is known about the 
actual impact of the HMR program in Malaysia. This study was to evaluate the 
impact of HMR program on schizophrenia patients‟ medication adherence, 
knowledge, quality of life, satisfaction to the program and the total cost saving from 
overstocked medications. This prospective longitudinal study was conducted from 
September 2012 to December 2013 and involved a convenience sampling of 133 
schizophrenia patients under follow up of the home care team of Hospital Bahagia 
Ulu Kinta. After attaining written informed consent, patients were visited by the 
pharmacist to perform comprehensive medication review and provide individualized 
medication counseling at home. Standardized data collection forms were used to 
collect data from patient during the first visit (baseline), second visit (after one 
month), third visit (after three months) and fourth visit (after six month). Medication 
adherence was evaluated by validated medication adherence rating scale (MARS) 
and pill count method. Patient‟s knowledge of antipsychotics and satisfaction 
towards HMR program were assessed by standardized questionnaires formulated by 
the researcher of this project. Quality of life was measured by the Sheehan Disability 
Scale (SDS). Any overstocked medications were collected and recorded for cost 
saving analysis. Friedman ANOVA test was used to compare the differences of the 
xiii 
 
outcome measured at baseline, one month, three months and six months follow up 
visit. The mean age of 133 patients was 41.76 (SD 8.86) years, with approximately 
equal ratio of males to females (54.9% vs 45.1%). MARS score showed medication 
adherence was significantly improved at all time points [first visit: median MARS = 
9 (IQR 3) vs fourth visit: median MARS = 10 (IQR 1), p < 0.001] while pill count 
method also revealed that percentage of doses taken had a highly significant 
improvement after the fourth visit [first visit: median = 67.1% (IQR 92.1%) vs 
fourth visit: median = 97.5% (IQR 14.3%), p < 0.001]. The knowledge score had 
also improved considerably after the implementation of HMR program [first visit: 5 
(IQR 2.5) vs fourth visit: 8 (IQR 1.0), p<0.001]. Regarding patient‟s quality of life, 
there was a significant improvement for „social‟ and „family‟ components after 
fourth visit (p  0.001). However, no difference was seen for overall quality of life 
of the patients, p=0.600 and for the „work‟ component (p = 0.486). The reduction of 
medication wastage was 26.5% after six months of HMR program. At the end of the 
study, patients generally showed positive satisfaction and acceptance towards HMR 
program provided by pharmacist. In conclusion, the HMR program has positive 
impact on schizophrenic patient‟s medication adherence, knowledge of 
antipsychotics, medication wastage reduction, service satisfaction and quality of life 
on „social‟ and „family‟ component.  
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CHAPTER 1 
GENERAL INTRODUCTION 
 
1.1 Introduction 
Schizophrenia is a chronic and serious mental illness, profoundly affecting patient‟s 
emotions, thinking and behavior. It is presented with positive symptoms of 
delusions, hallucinations and negative symptoms of affective flattening, alogia or 
avolition. Patients with schizophrenia can have cognitive deficits and impaired 
psychosocial functioning as well (American Psychiatric Association, 2000a). 
Information from World Health Organization stated that schizophrenia affects about 
21 million people across the world (World Health Organization, 2014). Patients with 
schizophrenia have high risk for suicide. Out of one-third of patients who attempted 
suicide, about one out of ten took their own lives eventually (Centers for Disease 
Control and Prevention, 2013). The patients who have deterioration in psychosocial 
functioning and risk of harming themselves or others will be admitted to the hospital 
(Ministry of Health Malaysia, 2009).  In Malaysia, there are increasing trend of 
patient newly diagnosed with schizophrenia. The prevalence of new cases of 
schizophrenia is about 100/100,000 per year (National Mental Health Registry, 
2008). Comprehensive psychiatric services are available to mental illness patients 
such as outpatient care, inpatient care, rehabilitative services and hospital-based 
outreach community psychiatric services (Ministry of Health Malaysia, 2011b). For 
instances, home care service in Hospital Bahagia Ulu Kinta was formalized since 
year 2002 with ongoing improvements in line with of Mental Health Act (MHA) 
2001 and Mental Health Regulations (MHR) 2010. The MHR 2010 Part III, Section 
16 has stated that the medical director or a license personal in charge shall ensure 
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the establishment of a community mental health team for community mental 
healthcare services in a psychiatric hospital or community mental health centre. The 
community mental health team shall consist of multidisciplinary personal. Thus, the 
concept of assertive community treatment is applied and customized to the local 
needs.   
 
Despite the availability of various psychiatric services and effective treatment for 
schizophrenia, low adherence rate to the prescribed antipsychotics is a major cause 
of psychotic relapse. The non-adherence rate is about 50 percent for people with 
schizophrenia who were discharged after one year and 75 percent after two years 
(Young et al., 1986, Weiden et al., 1991, Serban and Thomas, 1974, Barkhof et al., 
2012, Klingberg et al., 2008). Indeed, the average risk of relapse is 3.7 times greater 
in patients who were not adhering to the treatment compared with patients who 
adhered to antipsychotic regimens (Fenton et al., 1997). There are many factors that 
influence patient adherence to antipsychotic treatment, which include lack of insight, 
medication side effects, complexity of prescribed drug regime as well as the degree 
of family or social support (Young et al., 1986, Perkins, 2002). 
 
Antipsychotic drugs are identified as most frequently contributed to overall 
medication problems at the community setting such as nursing home. The common 
problems were adverse drug reactions, inappropriate treatment and underuse of 
beneficial treatment (Ruths et al., 2003). The rate of inappropriate prescription of 
psychoactive drugs was approximately 50% had been seen in US and Northern 
Ireland homes (Patterson et al., 2010). Side effects of antipsychotics that developed 
early in treatment can cause non-adherence to the medication. This is because 
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antipsychotics have delayed onset of action whereby patients experience side effects 
of antipsychotics before the intended positive outcomes from the treatment (Van 
Putten et al., 1984). The extrapyramidal motor symptoms, sexual disturbances and 
weight gain are significant side effects of antipsychotics that patients worried with 
(Fleischhacker et al., 1994). Further compounding this problem is the inadequate 
clinical information on medications received by the patients and care givers. This is 
usually too complicated for them to understand the information in the product leaflet 
especially for those from low levels of education or non-English educational 
backgrounds (Hussainy et al., 2011). Therefore, patients and care givers will 
normally search for other primary and secondary sources of information such as 
personal‟s opinions or experiences, occasionally information from the internet of 
undetermined sources. This will influence the decision of the patients and may lead 
to patients choosing for inappropriate treatment or discontinue the medications by 
themselves with subsequent potentially harmful outcomes (Hussainy et al., 2011). 
 
Pharmacy practice has now shifted towards patient care (Hassali et al., 2014, 
Pharmaceutical Services Division and Ministry of Health Malaysia, 2013) by 
increasing medication knowledge and enhancing treatment adherence so as to 
improve their social and occupational functioning, with better quality of life. One of 
the advancement is the development of home medication review (HMR) service 
conducted by pharmacist to identify and facilitate problem solving skills regarding 
the issue of medication non-adherence at patient‟s home (Ministry of Health 
Malaysia, 2011a). Patient‟s inability to manage medications properly is a common 
problem at home, particularly for patients taking multiple medications (Stuck et al., 
1994).
 
Inadequate medication management often stems from poor medication related 
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knowledge and understanding
 
(Armes and Addington-Hall, 2003),
 
and can lead to 
non-concordance with medication regimens which include medications not being 
taken, taken the wrong way or in the wrong dose. These in return can result in 
substantial treatment issues for the patients with impacts on their quality of life as 
well as indirect expenditures, such as psychological, social and economic burdens 
on patients, care givers and the healthcare system. These indirect expenditures are 
generally much greater than the costs of pharmacological and non-pharmacological 
treatments for the government (National Cancer Control Initiative, 2003). 
 
HMR program conducted by pharmacist is one of the options available to help 
patients who are at risk of experiencing medication-related problems at their home. 
Patient‟s medication adherence was assessed though patient‟s feedback, pill counts 
and identification of expired or unused medications (Papastergiou et al., 2013). It 
empowers and encourages the patients to take responsibility for their medicines and 
health by feeling comfortable enough to ask pharmacists about anything of which 
they are unsure. Patients play a key role in decision-making regarding their 
treatment and self-management strategies (Carter et al., 2012a). The program 
involves a team approach, whereby the doctor, pharmacist and other relevant 
members of the health care team working together to provide care for the patients. 
Pharmacist is part of a multidisciplinary team and plays a proactive role in ensuring 
medication adherence of all patients under the home care team. The pharmacist will 
visit the patients at their home, performs a comprehensive review of medication 
regime (including over-the-counter and complementary medicines) in the home 
setting and feedback to the doctor via a report or during daily review. The doctor 
will discuss any recommendations with pharmacist and may make appropriate 
5 
 
changes to patient‟s medication regime (Ministry of Health Malaysia, 2011a). 
Although time consuming, HMR gives patients satisfaction through a better 
pharmacist-patient relationship which is worth the effort. The pharmacist‟s 
involvement and contributions can potentially improve the patients‟ medication 
management and reduce their risk of non-concordance and hospital admissions 
(Carter et al., 2012a, Roberts et al., 2001, Hanlon et al., 1996, Borgsdorf et al., 1994, 
National Health Service UK, 2000).  
 
HMR program had been incorporated into the Malaysian public health care system 
since 2004. In fact, the World Health Organization (WHO) and the European 
Council have stressed the importance of including community pharmacists, 
considered the health professional most readily accessible to patients, as an active 
member of the multidisciplinary HMR team with the aim of benefiting patients' 
health (World Health Organization, 1994, Council of Europe, 2001), including those 
suffering from mental disorders (World Health Organization, 2005). Pharmacist is 
responsible to provide systematic assessment of the patients‟ medications at their 
home which is effectively to identify, resolve and prevent drug-related problems 
(Roughead et al., 2009, Sorensen et al., 2004). However little is known about the 
impact of HMR program since its implementation in Malaysia particularly among 
the patients diagnosed with schizophrenia (World Health Organization, 2003). 
 
1.2 Justification for this study 
Non-adherence and inappropriate medication use in the community and institutional 
settings has been reported to be a common and continuing problem in both local and 
overseas setting, particularly in patients taking multiple types of medications 
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(Rubio-Valera et al., 2009, Chen et al., 2012b, Ramli et al., 2012, Razali and Yahya, 
1995). Under-utilization of psychiatric services and non-adherence to the 
medications are the common issues at home for psychiatric patients which 
subsequently lead to a failure in achieving treatment goals. One of the methods to 
address medication-related problems is to conduct comprehensive medication 
reviews and related interventions by pharmacist as part of a multidisciplinary team 
process (Sorensen et al., 2004).
 
Visiting patients in the home by pharmacist indicates 
pharmacy service has shifted traditionally from product centered towards patient 
care. HMR program is assisting individuals living at home to maximize the benefits 
of the treatment as well as to detect, resolve and prevent medication-related 
problems. Patients‟ and care givers‟ medication-related knowledge and 
understanding of the illness also improved after pharmacist‟s domiciliary visit 
(Hussainy et al., 2011, Carter et al., 2012a). Studies of pharmacist medication 
reviews at home in Australia had positive impacts on medication care (Sorensen et 
al., 2004). This best practice approach which involves cooperation of the doctor, 
pharmacist, other relevant health professionals, patient and care taker facilitates 
cooperative working relationship between members of the health care team in the 
interests of patient health and wellbeing which is advocated by MHA 2001 and 
MHR 2010. 
 
To the best of our knowledge, there is limited study conducted to evaluate the 
impact of HMR program in Malaysia. As patients with schizophrenia are among the 
group of patients with higher tendency to use psychotropic medications 
inappropriately (Everard, 2005), there is a strong need to assess the effect of HMR 
service targeting at this population. This study therefore aims to evaluate the impact 
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of HMR program performed by pharmacist on the patients diagnosed with 
schizophrenia. The patients‟ adherence, knowledge, quality of life and the cost 
saving from declining medications wasted were assessed in this study. The findings 
of this study will help in providing recommendations to improve the standard Home 
Medication Review Protocol and its implementation in the Home Care Team, 
Hospital Bahagia Ulu Kinta, Perak, Malaysia.    
 
1.3 Objectives of this Study 
1.3.1 General Objective 
To evaluate the impact of the home medication review program conducted by the 
pharmacist for patients diagnosed with schizophrenia enrolled under the home care 
team, Hospital Bahagia Ulu Kinta, Perak, Malaysia. 
 
1.3.2 Specific Objectives 
1) To assess the impact of HMR program by pharmacist on medication adherence 
for patients diagnosed with schizophrenia. 
2) To evaluate the patients‟ knowledge towards antipsychotic agents before and 
after the HMR program conducted by pharmacist. 
3) To calculate the total cost saving resulting from the unused antipsychotic agents 
collected from patient‟s home during the pharmacist HMR visit. 
4) To determine the effect of HMR program on the quality of life of the patients by 
using Sheehan Disability Scale (SDS).  
5) To evaluate patient‟s satisfaction towards HMR service. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Overview 
A systematic literature search was conducted by using ScienceDirect, Scopus, 
SpringerLink, Wiley online library, SAGE Journals, Lippincott Williams & Wilkins 
Journals@Ovid, Cochrane Library, Medline (Abstracts) and Pubmed (Abstracts) 
electronic databases from year 1974 to 2014 to identify all relevant articles. 
Keywords for the search terms were „„mental health‟‟ or „„psychiatry‟‟ or 
„„psychiatric‟‟ or “schizophrenia” in combination with “home medication review” or 
“domiciliary medication review” or “pharmacist-led medication review”. The 
references section of the articles obtained were used for further search too. The 
articles that published in English language were included. The most recent 
publication was chosen if abundant abstracts of the same topic were obtained. 
 
2.2 Medication Misadventure at Home 
Globally, medication misadventure is a leading public health issue which covers 
broad array of negative drug experiences. It is defined as any iatrogenic hazard or 
incident associated with drug therapy (Kaboli et al., 2010).  For instance, medication 
errors, adverse drug reactions and the harms resulting from the errors are associated 
with medication misadventures (Manasse, 1989). Serious, harmful, poor clinical 
response and life threatening medication misadventures at home can lead to hospital 
admission. A systematic review by Runciman and colleagues in Australia revealed 
about 2 to 4% of all hospital admissions were drug-related which stemmed from 
medication misadventure (Runciman et al., 2003). Based on the findings of the 
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authors, up to three quarter of the admissions were either definitely or potentially 
preventable (Runciman et al., 2003). Another review on 15 studies on this topic in 
2002, Winterstein et al. reported a median of 7.1% were medication-related hospital 
admissions (Winterstein et al., 2002). Other observational studies in different 
countries also estimated the percentage of drug-related admissions were between 
2.3% to 16.2% and more than half of the cases actually can be prevented (Jha et al., 
2001, Howard et al., 2003, Nelson and Talbert, 1996). While in Malaysian context, a 
recent prospective study conducted by Karuppannan et al. in two medical wards in 
Malaysia reported as high as 36.9% (n = 443/1200) of admissions were related to 
adverse drug events (Karuppannan et al., 2013). 
 
The burden of mental illness is about twelve percent of the global burden of disease 
and most of the mental illness cases are managed in the community (World Health 
Organization, 2013). Antipsychotic medication is one of the main effective 
treatments for mental illness. However, psychotropic medications are always used 
incorrectly which causes medication misadventure (Mort and Aparasu, 2002). Based 
on a multidisciplinary review of drug utilization among nursing home residents, 
antipsychotic agents were mostly involved in medication problems such as adverse 
drug reactions which was the highest reported (Ruths et al., 2003). The expanding of 
pharmacist‟s role to provide community-based services to mentally ill patients who 
are at high risk of medication misadventure is an approach to improve psychotropic 
medication use (Bell et al., 2005). The systematic review by Bell et al. provided 
evidence that pharmacist conducted medication review can optimize the use of 
antipsychotic medications in the community setting (Bell et al., 2005). 
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By preventing medication misadventure, it is believed that this will reduce the health 
care cost burden besides improving patient‟s health outcomes and reducing 
medication-related hospital admissions. Among the studies which evaluated the cost 
burden caused by medication misadventures, one of the biggest studies involving 
18820 patients in two large general hospitals in Merseyside, England revealed that 
such admissions cost up to 466 million pounds annually (Pirmohamed et al., 2004). 
Another data from nested case-control study in 1997, reported that a total of $5.6 
million annually had been attributed from the admissions caused by adverse drug 
events (Bates et al., 1997). Medication misadventure can happen in patients‟ home 
upon discharged due to the confusion with the treatment and medication non-
adherence.  For instances, patients might take the medications wrongly in improper 
dose because of lack of knowledge and poor adherence to the medications (The 
Pharmacy Guild of Australia, 2009, Procyshyn et al., 2010). Subsequently, they 
were at high risk to encounter medication problems and might cause an admission if 
in serious case. This issue has become a worldwide concern and is preventable, 
better preventive efforts are urgently needed in order to avoid the problems from 
worsening. The development of the continuity care would be a good strategy to 
facilitate the continuum of the quality use of medicines from hospital to community 
setting.  
 
2.3 Risk of Medication Misadventure with Patients diagnosed as 
Schizophrenia 
Person with mental illness are known with diminished cognitive capacity and are 
similarly exposed to the risk of medication misadventure (Campbell Research & 
Consulting, 2008). In addition, all psychotropic drugs are common with adverse 
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drug reaction which is an example of medication misadventure (Ruths et al., 2003). 
This in return will increase the risk of medication misadventure among the mentally 
ill patients.  There are bundle of studies which had shown the incidence and causes 
of medication misadventure among individuals with mental illness. (Maidment et al., 
2006, Procyshyn et al., 2010). 
 
Maidment et al. conducted a systematic review on hospital-based psychiatry service 
and the medication dispensing process by pharmacist. The review pointed out that 
psychiatric patients are at higher risk of medication misadventure as this group of 
patients are putting responsibilities on mental health staff with less articulate and 
question about the potential side effects, change of the treatment regimen and the 
monitoring requirement (Maidment et al., 2006). The review was focused on process 
based and not on outcome based studies. Outcome based studies were retrospective 
review on historical medical notes that had reported harm to the patients caused by 
medication. While process based studies were prospective review on prescriptions 
by pharmacist to prevent harm and error caused by medication. Therefore, the 
systematic review on process based studies noted there were errors reported which 
did not reach patients with serious harm such as adverse drug events and iatrogenic 
injury. Most errors reported were prescribing errors (illegibility, incomplete 
prescriptions and transcription errors) and administration errors (wrong time, wrong 
dose and missed dose) (Maidment et al., 2006). Another comprehensive review by 
Procyshyn et al. identified the contributing factors to the medication errors in 
psychiatry. The review noted that the misadventure can be originated from patient, 
mental health care provider and system. The patient-related factor would be poor 
medication adherence, failure to tell the presented psychiatric symptoms and inform 
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their mental health care providers about their latest treatment (Procyshyn et al., 
2010). Both reviews from Maidment et al. and Procyshyn et al. highlighted the need 
of seamless continuity of care and adequate clinical pharmacy practice (Maidment et 
al., 2006, Procyshyn et al., 2010). 
 
2.4 The Causes of Medication Misadventure in Patients with Schizophrenia 
2.4.1  Poor Medication Adherence  
The previous reported mean non-adherence rate to antipsychotics among 
schizophrenia patients was about 49.5% (Lacro et al., 2002). It is often associated 
with potentially severe clinical outcomes. For instances, it shows an increased risk 
of relapse and is seen as a major problem which prevents patients with 
schizophrenia from living independently in community settings. Based on a recent 
update from a systematic review by Zipursky et al., a mean of 77% relapse rate 
following one year of stopping antipsychotic medications by patients were found. 
The risk had increased to 90% after two years (Zipursky et al., 2014). According to a 
prospective study, around one third of the patients who had poor insight were tended 
to stop the treatment within six months of their first psychotic episode during early 
stage of the illness (Kamali et al., 2006). The finding was also supported by a two 
years prospective study by Linden et al., which reported 34.4% of the patients 
refused psychiatry follow up and stopped the medications. These patients were from 
young age group and with shorter duration of mental illness. They were more likely 
to miss the follow up after discharged from hospital and not keeping mental health 
outpatient appointments regularly (Linden et al., 2001). 
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A comprehensive review by Acosta et al. postulated a number of risk factors 
associated with medication non-adherence, for instances, history of poor adherence, 
poor rapport with the psychiatrist, shorter duration of illness, without an adequate 
follow up plan upon discharge, distress with the side effects, inadequate treatment 
with residual symptoms and believing the illness does not need a long term 
treatment (Acosta et al., 2012). For patients with younger age and shorter duration of 
illness, they may distrust the diagnosis and the importance for treatment, and show 
poorer tolerance to adverse effects caused by the medications at the beginning of the 
illness (Acosta et al., 2012, Mahaye et al., 2012). Besides, the disease severity and 
the unique characteristics of schizophrenia such as cognitive impairment were 
associated risk factors for medication non-adherence as well. These disease related 
factors can be explained by the deficiency of memory and concentration which led 
to the difficulty of comprehension and organization of their medication schedules 
(Acosta et al., 2012, Higashi et al., 2013). 
 
As a consequence of antipsychotics non-adherence, patients are posed at a higher 
risk of medication misadventure which can lead to poorer prognosis, relapse, 
readmission and longer remission time (Acosta et al., 2012). Furthermore, the 
antipsychotic non-adherence has a definite relationship with the incurred economic 
costs. The significant direct costs would be the issue of rehospitalization (Thieda et 
al., 2003, Weiden and Olfson, 1995). In the UK, the predicted excess total inpatient 
service cost for non-adherent psychiatric patients as compared to the adherent 
psychiatric patients was over 5000 pounds per year (Knapp et al., 2004). Since 
patients with severe mental illness such as schizophrenia have complex cognitive 
features, a specific intervention to improve their medication adherence is required. 
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2.4.2 Poor Insight 
Insight into illness is a determinant value for the treatment outcomes in 
schizophrenia, particularly to improve the medication adherence, and to reduce the 
risk of relapse and rehospitalization. According to the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV), lack of insight is a common 
phenomenon among mental illness patients and it may be one of the best predictors 
of poor outcome.  This is because it predisposes the patients to non-adherence with 
treatment (American Psychiatric Association, 2000a). Literatures reported that 
higher level of insight into illness correlates with better treatment adherence and 
medication response (Schwartz et al., 1997, Schennach et al., 2012). People tend to 
view mental illnesses in different ways. For example, in Chinese culture, they hold 
an integrated point of view that supernatural attributions are usually causing mental 
illness (Song et al., 2005, Lauber and Rossler, 2007). Two studies conducted in 
Taiwan in 1981 and in 1991 showed that up to 15% of the population linked 
spiritual explanations to mental illnesses, and with that they opted and believed in 
folk therapy rather than sought for psychiatric treatment (Chen et al., 2012a). These 
cultural attitudes can affect patient‟s insight towards mental illness and their 
acceptance to the medication significantly. For instances, some literatures suggest 
that Chinese culture imposes greater stigmatizing attitudes to mentally ill patients 
compared to other cultures such as the Western culture (Hsiao et al., 2006, Lauber 
and Rossler, 2007, Mellor et al., 2012). Patients in this Chinese stigmatizing culture 
tend to deny their illness, refuse to be admitted when in need of hospitalization and 
discontinue prescribed medications after discharge. This is consistent with a study 
finding which demonstrated significant lower levels of insight and less positive 
attitudes towards medication among Chinese sample from Guangzhou, China as 
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compared to the United States Clinical Antipsychotic Treatment for Intervention 
Effectiveness (US CATIE) sample (Mohamed et al., 2014). Furthermore, patients 
with perception of their antipsychotics treatment is ineffective and causes lots of 
side effects are likely not to fill their prescription and take the medications as 
prescribed. Study by Kamali et al. claimed that poor insight is a strong predictor 
which caused 33% of patients who encountered first episode of schizophrenia had 
stopped their treatment within 6 months (Kamali et al., 2006). Atkinson et al. also 
postulated that bad medication experience increases the risk of poor medication 
adherence (Atkinson et al., 2004). A study by Amador et al. showed deficits of self 
awareness in patients with schizophrenia were much more severe than patients with 
schizoaffective or major depressive disorders with or without psychosis (Amador et 
al., 1994). Therefore, a critical look at the relationship between awareness of mental 
disorder and its impact on patient‟s outcomes is utmost important.  
 
2.4.3 Lack of Medication Knowledge 
Managing medications wrongly is the major problem patients encounter at home 
which can lead to misadventure and rehospitalization (Hussainy et al., 2011). 
Medication taking decision and awareness of the illness are influenced by the 
patient‟s level of understanding on the illness and treatment. This is especially 
important for the younger patients who encounter recent onset of schizophrenia as 
compared to the multi-episode patients. The treatment normally will involve both 
patients and their families who are lacking of information in this field (Grubic and 
Tavcar, 1999, Robinson et al., 2002). Their poor understanding about the important 
benefits and possible side effects of the antipsychotics may lead to medication 
refusal and relapse. This proves the need of information and the two-way 
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communication between mental health care provider and patients. In addition, 
cognitive deficiencies will affect patients‟ ability of judgment and master new 
knowledge about their illness and treatment as well (Acosta et al., 2012). 
 
Implementing education program to the patients and their families may provide 
related information about the illness and treatment to increase their understanding 
and promote medication adherence. The efficacy of a comprehensive educational 
program such as psychoeducation had been proven to improve patient‟s knowledge, 
reduce psychotic symptoms and relapsing rate (Li and Arthur, 2005, Chan et al., 
2009). A Malaysian study had reported positive outcomes on insight and reduction 
of admission rate after evaluating the impact of psychoeducation to patients with 
schizophrenia (Ruzanna et al., 2010). Such program can decrease the patients‟ 
negative thoughts of medication side effects, increase patients‟ confident on 
medication and subsequently improve the medication adherence. Further, younger 
generation of schizophrenia patients gain more from psychoeducation as compared 
to those with advanced age. This is because of the cognitive and memory issue 
around the older patients which suggesting that they have illness related limitation to 
learning (Ruzanna et al., 2010).  
 
In short, the potential medication misadventure resulting from poor knowledge 
about illness and treatment for schizophrenia can be avoided by implementing 
education program such as psychoeducation program.  
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2.4.4 Poor Family Support 
Rejection and poor family support is the main perpetuating factor which causes 
inadequate treatment of schizophrenia (Chen et al., 2012a). Family members or 
caregiving relatives have important role in facilitating patient‟s adaption to illness, 
improving medication adherence and promoting recovery (Magliano et al., 2005). 
However, Chatterjee and colleagues found out there were 31% of families which 
had been rated as not being supportive when they were collecting study sample 
characteristics for their study. They reported that poor family support was correlated 
with longer duration of illness (Chatterjee et al., 2009). Previous studies had found 
that expressed emotion from the families can predict the repeatedly relapse in 
patients with schizophrenia. Expressed emotion is an adverse family environment in 
which the patients received a number of critical comments and marked degree of 
emotional over involvement from family members. This would cause patients to be 
more likely to have symptoms exacerbation and relapse (King, 2000, King and 
Dixon, 1999). 
 
Lack of family‟s supervision on patient‟s treatment is another commonest factor 
associated with poor prognosis of the disease and longer duration of untreated 
psychosis.  Due to the frequent psychotic symptoms at home, patients are more 
likely to be rejected by their overburdened family (Chen et al., 2012a), and 
subsequently lead to homelessness. Hence, studies showed patients with 
schizophrenia are having greater risk of homelessness as compared to the other 
psychiatric patients (Bebbington et al., 2005, Brekke et al., 2001, Chatterjee et al., 
2009). 
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There is growing recognition of family intervention as an adjunct to the treatment of 
antipsychotic. One of the recent Cochrane review on 53 randomized controlled trials 
(RCTs) revealed that the family support on patients with schizophrenia can lead to 
the improvement of medication adherence, the reductions of psychotic symptoms,  
relapse and rehospitalization (Pharoah et al., 2012). In a Malaysian study, provision 
of psychoeducation program to the family members or caregivers demonstrated 
significant improvement in their knowledge of the illness symptoms, the importance 
of the treatment and the early warning signs. Moreover, the defaulter rate for 
patient‟s follow up was reduced after the psychoeducation program (Paranthaman et 
al., 2010). 
 
In conclusion, many studies in the past have ascertained the value of family support 
and involvement for the treatment of schizophrenia patients. In addition, patients 
who stay with their families would have more contact and support from the family 
members. This would be an advantage for the patients‟ recovery. Thus, the 
preference of families to participate into mental health care of the patients should be 
reinforced to prevent the illness deterioration.  
 
2.4.5 Stigmatization 
The stigma of mental illness is a well documented cause of a person‟s reluctance or 
delay to seek effective mental care treatment, social withdrawal, lower self-esteem, 
poor self-care and substance misuse (O'Reilly et al., 2013, Sartorius, 2007). In a long 
run, mental illness patients with a low treatment effect will increase the probability 
of the illness relapse. Stigma comes from the public towards person with mental 
illness such as schizophrenia is high, particularly due to the perception that this 
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group of people is dangerous (Lauber and Rossler, 2007). According to the General 
Social Survey (GSS) 1996 conducted in United States, more than half of the 1444 
surveyed adults were not willing to socialize, work next to or have a family member 
marry to a person with mental illness. Nearly 50% of the GSS 1996 sample agreed 
that patients with schizophrenia should be forced to get treatment (Pescosolido et al., 
1999). A recent meta-analysis of international studies done by Schomerus et al. had 
shown that mental health stigma towards people with mental illness remained 
unchanged for the past two decades although public‟s level of mental health literacy 
had increased in recent years (Schomerus et al., 2012). Negative attitudes can raise 
the stress to the mentally ill patients and rob their opportunities to deserve better 
quality of life, good jobs and satisfactory health care (Song et al., 2005, Patrick et al., 
2002). They not only struggled with the discrimination from the public but also 
challenged by the symptoms from the disease as well as from family members.  A 
study by Thornicroft et al. on 729 patients with schizophrenia across 27 countries 
found that about 50% of them experienced and anticipated discrimination from 
family members, in making or keeping friends, in finding or keeping a job and in 
intimate or sexual relationships. The discrimination rate was high and consistent 
across countries (Thornicroft et al., 2009). In addition, numerous studies revealed 
that Chinese community put heavily stigmatizes on mentally ill patients. They 
labeled mentally ill people as useless, incompetent, failure to fulfill cultural 
expectations and familial obligations. Consequently, the mentally ill patients 
experienced rejection and interpersonal disharmony (Hsiao et al., 2006, Lauber and 
Rossler, 2007, Mellor et al., 2012, Yang et al., 2007, Yang, 2007). 
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2.5 The Consequences of Medication Misadventure in Patients with   
Schizophrenia 
2.5.1  Psychosis Severity and Relapse 
For patients who are discharged from hospital to their home, maintenance treatment 
with antipsychotics is important to prevent patients from relapse. The NICE 
guidelines also stated about the importance of long term maintenance of 
antipsychotics in relapse prevention (National Institute for Health and Clinical 
Excellent, 2014). However, patients who missed appointments have high prevalence 
of dropout from treatment and subsequent poor prognosis. It is supported by a 
prospective study on 365 patients who received mental healthcare, the result showed 
that patients who missed an appointment were more functionally impaired, unwell 
and subsequent more admissions than those who attended appointments (Killaspy et 
al., 2000). A study carried out by Jaeger et al. found that patients who discontinued 
the psychiatric maintenance treatment had the highest rate of being rehospitalized 
compared to patients who adhered to the treatment during the six months follow up 
(Jaeger et al., 2012). 
 
Apart from distressing rehospitalization, relapse cases were also associated with the 
positive and negative symptoms exacerbation which required more intensive case 
management, changed of antipsychotic agent and appeared to have lower QoL 
(Almond et al., 2004, Briggs et al., 2008, Chabungbam et al., 2007). Not 
surprisingly, relapse cases were generating higher cost to the health care system 
compared to the stable patients. Although not all relapsing patients were admitted, 
the changed of the treatment cost, increased psychiatric outpatient visits and 
intensive community psychiatric service should be taken into account as well. 
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Almond et al. found that the relapse cases cost four times higher than the stable 
patients (Almond et al., 2004). 
 
Chabungbam et al. found that medication misadventure is related to relapse in 
schizophrenia. Relapsed patients who reported with significant side effects of 
medications could be resulted from inappropriate dosage of the medications 
(Chabungbam et al., 2007). Discontinuing medication seems logical to many 
patients and is tempting when the psychotic symptoms subsided. Patients who tend 
to discontinue their treatment or partially adhere to the medications are a strong 
predictor to cause relapse as stated in a few studies (Kozma and Weiden, 2009, 
Olivares et al., 2013, Weiden et al., 2004).  
 
2.5.2 Health Risk  
Leaving patients with mental health problems untreated at home can worsen the 
patients‟ outcomes, such as committing suicide and mortality. Globally, there is 
increasing trend of suicides among patients with schizophrenia and their lifespan 
was reduced by an average of 10 years (Saha et al., 2007). According to Malaysian 
data, approximately 10-15 in 100 of schizophrenia patients were found to have 
committed suicide as compared to 10 out of 100,000 people only among those with 
no mental illness (Malaysian Psychiatric Association, 2007). This is also supported 
by a meta-analysis by Brown and a study by Osby et al. in Sweden. They found a 
linear increasing trend of mortality among patients with schizophrenia (Osby et al., 
2000, Brown, 1997). The mortality rate for schizophrenia was highly associated with 
elevated suicide rate which attributed 28% of the total mortality rate (Brown, 1997). 
Increasing mortality from suicides was reported in a registry study from Denmark 
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and it shared the same conclusion in a Danish study which mentioned that the illness 
caused them to be less inclined to seek for treatment (Mortensen and Juel, 1993). 
Brown et al. found that one in four suicides were not in contact with psychiatric 
services (Brown et al., 2000). The mental disintegration resulting from rejecting 
psychiatric contact is the important predictor of suicide attempts. Hor and Taylor 
found an important finding in their systematic review that uncontrolled positive 
symptoms such as auditory hallucinations and delusions were associated with an 
increased risk of suicide among patients with schizophrenia (Hor and Taylor, 2010). 
Another protective factor that contributes to high suicide risk in schizophrenia is 
poor medication adherence (Hawton et al., 2005, Hor and Taylor, 2010). Tiihonen et 
al. reported a worrying 37-fold increase in mortality by suicides in a nationwide 
cohort of patients after a first episode of schizophrenia discharged from hospital and 
not taking antipsychotic medications (Tiihonen et al., 2006). Patients who were 
living alone or not staying with their families should be taken into account as it can 
affect the poor prognosis of the disease and increase the risk of suicide (Hawton et 
al., 2005). Prevention of suicide in schizophrenia will rely on patients adhere to the 
effective treatment and the support from family members. According to the review 
by Hor and Taylor, a smaller risk of committing suicide was found among 
individuals who were on treatment (Hor and Taylor, 2010). 
 
2.5.3 Low Quality of Life 
Quality of life (QoL) has been an important outcome measure to measure psychiatric 
patient‟s daily lives following deinstitutionalization (Xiang et al., 2007). The 
monitoring of symptoms recovery may not be adequate to understand and is 
insufficient to measure the efficacy of community care program. Indeed psychiatric 
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patients face many other challenges, such as marginalization and discrimination 
from the community, poor insight, limited rehabilitation resources available as well 
as the disabilities due to the disease (Xiang et al., 2007). In addition, the depressive 
symptoms in schizophrenia were significantly associated with poor quality of life 
that measured by Sheehan Disability Scale (SDS) (Rocca et al., 2005). Thus, the 
attempt to describe wider dimensions such as quality of life can provide better 
understanding of psychiatric patients living in the community. There are few studies 
which revealed that patients with schizophrenia had lower quality of life compared 
to the general population. For example, Lempp and colleagues recruited patients 
with schizophrenia found that they had significant impairments for their quality of 
life in physical and mental domains, assessed by the Short Form Health Survey (SF-
36) compared to the general population (Lempp et al., 2009). The German National 
Health Interview and Examination Survey (GHS) showed that patients with mental 
disorder had poorer quality of life on all SF-36 subscales and component scores 
compared to the community without mental illness (Schmitz and Kruse, 2007). 
Pertaining to the community based psychotic patients in Penang, Malaysia, Mubarak 
et al. revealed approximately 50% of 174 patients faced social discrimination, 
isolation, acute poverty and exploitation in the working place (Mubarak et al., 2003). 
This phenomenon also happened in developed countries such as the urban areas in 
Australia (Jablensky et al., 2000). Another study on Chinese outpatients with 
schizophrenia living with their families reported significant poor QoL in physical, 
psychological and social domains compared to the general population in Hong Kong 
(Xiang et al., 2007, Chan and Yu Iu, 2004). It is important to know that patients with 
impending relapse risk with severe positive symptoms and higher readmission rate 
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were significantly correlated with poorer QoL (Xiang et al., 2007, Chan and Yu Iu, 
2004). 
 
Other than SF-36 which is comprehensive but lengthy, Sheehan Disability Scale 
(SDS) is another tool to measure patient‟s quality of life. This is a short, easy to use 
and sensitive tool to measure the functional impairment in psychiatric disorders 
(Sheehan et al., 1996). In a study involved 1,001 patients to evaluate the internal 
consistency reliability and validity for SDS, the result showed that more than eighty 
percent of the patients with mental disorder had significantly elevated SDS score 
(higher impairment) than those who were not mentally ill.  The internal consistency 
reliability of the SDS found to be high, with a coefficient alpha of 0.89 (Leon et al., 
1997). Meanwhile, according to American Psychiatric Association, the sensitivity 
and specificity for SDS are 0.83 and 0.69 respectively in identifying psychiatrically 
impaired patients (American Psychiatric Association, 2000b). 
 
2.6 Continuity of Care - Community Psychiatry Service in Malaysia 
Whilst patients with schizophrenia are clearly susceptible to medication 
misadventure, two interfaces between hospital and community services had been 
created as a crucial step to help patients at their home. Based on international mental 
health care standards, many Western mental health systems have included 
community mental health care in their contemporary health policies and guidelines. 
In response to this global phenomenon, many countries in the Asia-Pacific region 
such as Malaysia had established National Mental Health Policy and guidelines in 
1998 to provide community mental health service (Ministry of Health Malaysia, 
2011b). This mental health service is important to facilitate early discharge, 
